Summary
The pharmacokinetics of ciprofloxacin has been studied after a single oral dose of 500 mg given to 5 normal subjects (N) and to 15 patients grouped according to their residual renal creatinine clearance: Group I, 8–30 ml·min−1, Group II, <8 ml·min−1, and Group III, haemodialysed patients studied twice — during an interdialysis period (IIIa) and in a 4 h haemodialysis session (IIIb). Ciprofloxacin was assayed by reverse phase HPLC using a spectrofluorimetric detection. The peak plasma concentration (2–5 mg·l−1) was reached within 2 h after drug administration. Apparent volume of distribution, 6.6 (N), 5.0 (I), 2.7 (II) and 4.2 (IIIa) l·kg−1 and total plasma clearance, 770 (N), 440 (I), 378 (II) and 314 (IIIa) ml·min−1 were decreased in relation to the degree of renal impairment. Mean plasma half-lives for patients in the 4 groups were 7.3 (N), 10.4 (I), 7.2 (II) and 9.3 (IIIa) h. In groups N, I and II, 40, 16 and 8% of the administered dose was eliminated through the kidney, with mean renal clearances of 305±63,61±21 and 21±3 ml·min−1. A linear relationship was found between the renal clearance of ciprofloxacin and the glomerular filtration rate (r=0.75,n=15). Ciprofloxacin was partly removed by haemodialysis (IIIb): the dialyser extraction ratio was 23% and the dialysis clearance was 40 ml·min−1.
Similar content being viewed by others
References
Bauernfeind A, Petermuller C (1983) In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2: 111–115
Chin NX, Neu HC (1983) Ciprofloxacin, a quinoline carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 24: 784–786
Goodman LJ, Fliegelman RM, Trenholme GM, Kaplan RL (1984) Comparative in vitro activity of ciprofloxacin againstCampylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother 25: 504–506
Van Caekenberghe DL, Pattyn SR (1984) In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substitued quinoline derivatives. Antimicrob Agents Chemother 25: 518–521
Wingender W, Graefe KH, Gau W, Forster D, Beermann D, Schacht P (1984) Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 3: 355–359
Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P (1985) Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27: 375–379
Wise R, Lockley RM, Webberly M, Dent J (1984) Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother 26: 208–210
Joos B, Ledergerber B, Flepp M, Bettex JD, Luthy R, Siegenthaler W (1985) Comparison of high pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother 27: 353–356
Yamoaka K, Nakagaw T, Uno T (1978) Statistical moment in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558
Gotch FA (1976) Haemodialysis: Technical and kinetic considerations. In: Brenner BM, Rector FC (eds). The kidney. Saunders WB company Philadelphia, pp 1672–1704
Crump B, Wise R, Dent J (1983) Pharmacokinetics and tissues penetrations of ciprofloxacin. Antimicrob Agents Chemother 24: 784–786
Aronoff GE, Kenner CH, Sloan RS, Pottratz ST (1984) Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther 6: [36]: 384–388
Hoffler D, Dalhoff A, Gau W, Beermann D, Michl A (1984) Dose and sex independant disposition of ciprofloxacin. Eur J Clin Microbiol 3: 363–366
Ledergerber B, Bettex JD, Joos B, Flepp M, Luthy R (1985) Effect of standard breakfast on drug absorption and multipledose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 27: 350–352
Fabre J, Balant L (1976) Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet 1: 99–120
Gibaldi M (1977) Drug distribution in renal failure. Am J Med 62: 471–474
Singlas E, Bourtron HF, Merdjan H, Brocard JF, Pocheville M, Fries D (1983) Moxalactam pharmacokinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 3: 403–407
Merdjan H, Baumelou A, Diquet B, Chick O, Singlas E (1985) Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis. Br J Clin Pharmacol 19: 211–217
Webb DB, Hughes PJ, Asscher AW (1985) Ciprofloxacin pharmacokinetics in patients with impaired kidney function. 14th International Congress of Chemotherapy, Kyoto, Abstract n° S-40.9
Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti Q, Manfrin M, Sega R, Gomeni R, Ponticelli C, Morselli PL (1976) Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis. Clin Pharmacokinet 1: 373–384
Balant L (1983) La clairance hépatique des médicaments dans l'insuffisance rénale. Néphrologie 4: 45–47
Boelaert J, Valcke Y, Schurgers M, Daneels R, Rosseneu M, Rosseel MT, Bogaert MG (1985) The pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother 16: 87–93
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Singlas, E., Taburet, A.M., Landru, I. et al. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. Eur J Clin Pharmacol 31, 589–593 (1987). https://doi.org/10.1007/BF00606636
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606636